Peter R. Galle
- Hepatology top 0.01%
- Epidemiology top 0.02%
- Oncology top 0.05%
- Molecular Biology top 0.2%
- Surgery top 0.05%
- Co-authors
- Markus F. NeurathVincenzo MazzaferroJosep M. LlovetAlejandro FornerJean‐Luc RaoulPeter SchirmacherFabio PiscagliaValérie Vilgrain
- Topics
- Liver Disease Diagnosis and Treatment (206 papers)Hepatocellular Carcinoma Treatment and Prognosis (180 papers)Liver Disease and Transplantation (105 papers)
- Cited by
- HepatologyOncologyImmunology
- Partner nations
- GermanyUnited StatesFrance
In The Last Decade
Peter R. Galle
1.2k papers receiving 54.5k citations
Hit Papers
Peers
Comparison fields: 5 of 216
- Hepatology 19.4k
- Epidemiology 16.1k
- Oncology 13.4k
- Molecular Biology 11.4k
- Surgery 11.0k
Countries citing papers authored by Peter R. Galle
This map shows the geographic impact of Peter R. Galle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter R. Galle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter R. Galle more than expected).
Fields of papers citing papers by Peter R. Galle
This network shows the impact of papers produced by Peter R. Galle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter R. Galle. The network helps show where Peter R. Galle may publish in the future.
Co-authorship network of co-authors of Peter R. Galle
This figure shows the co-authorship network connecting the top 25 collaborators of Peter R. Galle. A scholar is included among the top collaborators of Peter R. Galle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter R. Galle. Peter R. Galle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 3 | |
| 2 | 1 | |
| 3 | Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW.breakdown → | 75 |
| 4 | 13 | |
| 5 | 12 | |
| 6 | 2 | |
| 7 | 13 | |
| 8 | 23 | |
| 9 | 13 | |
| 10 | 21 | |
| 11 | 11 | |
| 12 | 6 | |
| 13 | 87 | |
| 14 | Cetuximab with irinotecan/NA-FA/5-FU as first-line treatment in advanced gastric cancer: Preliminary results of a non-randomised multi-centre AIO phase II study | 8 |
| 15 | 125 | |
| 16 | 87 | |
| 17 | 276 | |
| 18 | 490 | |
| 19 | 151 | |
| 20 | [Analysis of 366 traffic accident fatalities]. | 1 |
About Peter R. Galle
Peter R. Galle is a scholar working on Hepatology, Oncology and Epidemiology, having authored 1.2k papers that have together received 55.7k indexed citations. Recurring topics across this work include Liver Disease Diagnosis and Treatment (206 papers), Hepatocellular Carcinoma Treatment and Prognosis (180 papers) and Liver Disease and Transplantation (105 papers). The work is most often cited by research in Hepatology (19.4k citations), Oncology (13.4k citations) and Immunology (10.2k citations). Peter R. Galle has collaborated with scholars based in Germany, United States and France. Frequent co-authors include Markus F. Neurath, Vincenzo Mazzaferro, Josep M. Llovet, Alejandro Forner, Jean‐Luc Raoul, Peter Schirmacher, Fabio Piscaglia, Valérie Vilgrain, Ralf Kießlich and Wolfgang Stremmel. Their work appears in journals such as Science, Proceedings of the National Academy of Sciences and The Lancet.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.